Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As with all targeted therapies, the PD-L1 test needs a companion diagnostic to be developed and approved. Dako North America (part of Agilent) has submitted a Premarket Approval Application (PMA ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

NoMIS Power, a leader in advanced silicon carbide (SiC) power semiconductor technology, has announced a major breakthrough in improving the short-circuit withstand time (SCWT) of SiC MOSFETs. This ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

Here's a detailed comparison between the Realme P3 Ultra and iQOO Neo 10R. Find out which phone you should buy under Rs ...

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...